Rarity support Elicera Therapeutics in cutting edge CAR-T therapy study
On behalf of the sponsor, Elicera Therapeutics, Rarity is supporting the ELC301 translational study with analysis of the vector copy number (VCN) of integrated retroviral vectors in engineered Human T-cells. “The assay from Rarity shows similar or better CV than current available ddPCR assays, and a much more cost efficient alternative. Based on the sensitivity […]
